Cagrilintide Side Effects: What Clinical Trials Actually Show (2026)

Cagrilintide is gaining serious attention as a next-generation weight-loss peptide — and for good reason. Clinical data from phase 2 and phase 3 trials shows meaningful body weight reductions, with some participants losing over 15% of body weight when cagrilintide is combined with semaglutide. But before anyone considers this compound for research purposes, the side effect profile deserves an honest, numbers-driven examination.

This is not a hand-waving overview. This guide pulls directly from published clinical trial data — including the REDEFINE 1 phase 3 trial and multiple phase 2 dose-escalation studies — to give you the most accurate picture of what adverse events were actually reported, at what frequencies, and how serious they were. If you are researching cagrilintide, these are the numbers you need to know.

What Is Cagrilintide and Why Does Its Mechanism Matter?

Cagrilintide is a long-acting amylin analogue. Unlike semaglutide, which targets GLP-1 receptors, cagrilintide primarily activates amylin receptors — specifically the AMY1, AMY2, and AMY3 receptor complexes — along with calcitonin receptors. Amylin is a pancreatic hormone that works alongside insulin to regulate satiety, slow gastric emptying, and suppress glucagon secretion after meals.

This distinct mechanism is why cagrilintide's side effect profile differs in key ways from GLP-1 receptor agonists. The GI effects overlap, but the injection site reaction rates and some neurological effects are more pronounced with amylin-based compounds. Understanding the mechanism helps predict and contextualize which adverse events are most likely — and why dose escalation matters so much for tolerability.

In the REDEFINE 1 trial, participants received cagrilintide 2.4 mg subcutaneously once weekly over 68 weeks. Monotherapy produced an average body weight reduction of approximately 11.8%. When researchers combined cagrilintide with semaglutide 2.4 mg in the CagriSema arm of related trials, weight reductions climbed toward 15–22%, but the combined GI burden increased substantially.

Common Side Effects: The Numbers From Clinical Trials

The following adverse events were reported in ≥5% of participants in phase 2 and phase 3 trials. These are the side effects a researcher or participant should expect to encounter, particularly during the dose-escalation phase.

Nausea

Nausea is the most frequently reported side effect of cagrilintide across all trials. In phase 2 dose-finding studies, nausea rates varied considerably by dose: lower doses (0.3–0.6 mg) produced nausea in roughly 20–25% of participants, while the highest studied dose of 4.5 mg pushed that figure toward 47%. At the clinically relevant 2.4 mg maintenance dose used in REDEFINE 1, nausea affected approximately 33–40% of participants at some point during treatment.

Importantly, nausea was predominantly reported as mild to moderate in severity. The vast majority of cases occurred during the dose-escalation period — the weeks when doses are being stepped up toward the maintenance level — rather than persisting chronically throughout the treatment period. This pattern is consistent with other peptide-based weight loss agents and underscores the importance of slow, structured dose escalation.

Injection Site Reactions

This is where cagrilintide diverges notably from GLP-1 receptor agonists. Injection site reactions — including erythema (redness), nodules, pruritus (itching), and pain — occurred at rates dramatically higher than placebo and meaningfully higher than what is typically reported with semaglutide. In some phase 2 cohorts, injection site reactions affected up to 38% of participants versus single-digit percentages in placebo groups.

The reaction profile is thought to be related to cagrilintide's fatty acid side chain and the depot it forms under the skin after subcutaneous injection. Most reactions were localized, self-limiting, and did not require treatment discontinuation. However, rotating injection sites is considered essential protocol for minimizing recurrence and severity.

Vomiting

Vomiting followed a similar pattern to nausea — dose-dependent, most common during escalation, and predominantly mild to moderate. Across the clinical program, vomiting affected approximately 10–20% of participants, with higher rates at elevated doses. Severe vomiting leading to dehydration or requiring medical intervention was rare but documented in a small subset of participants.

Constipation

Constipation affected 8–16% of participants across studies. This is consistent with cagrilintide's mechanism: slowing gastric emptying and reducing gut motility are direct pharmacological effects of amylin receptor activation. Constipation was generally manageable with dietary adjustments and hydration, and rarely required treatment discontinuation.

Diarrhea

Reported in 8–14% of participants, diarrhea was less common than constipation but still notable. Interestingly, some participants experienced alternating constipation and diarrhea, reflecting the compound's significant effect on gastrointestinal motility throughout different segments of the GI tract.

Decreased Appetite

While this is technically a desired pharmacological effect rather than an adverse event, decreased appetite was reported by participants and tracked separately in trials. Significant appetite suppression was noted in 15–30% of participants and occasionally contributed to inadequate caloric intake, nausea amplification, or fatigue — making it worth monitoring in a research context.

Uncommon Side Effects Worth Monitoring

The following adverse events occurred in fewer than 5% of participants but were consistently documented across trials, making them clinically relevant for anyone conducting or monitoring research with cagrilintide.

Headache and Dizziness

Central nervous system effects — particularly headache and dizziness — were reported in roughly 3–5% of participants. These may relate to cagrilintide's central amylin receptor activity in the area postrema and hypothalamus, brain regions involved in appetite regulation and emesis. Dizziness was occasionally associated with nausea episodes but also occurred independently.

Fatigue

Fatigue was reported by approximately 3–6% of participants across trials. This likely reflects a combination of caloric restriction secondary to appetite suppression, as well as potential direct central effects of amylin receptor activation. Fatigue was typically mild and most pronounced during the first four to eight weeks of treatment.

Hypoglycemia Risk in Combination Protocols

When cagrilintide is used alongside glucose-lowering agents — particularly insulin or sulfonylureas — the risk of hypoglycemia increases. Cagrilintide suppresses glucagon secretion, which is a protective mechanism against low blood glucose. In trials involving participants with type 2 diabetes on insulin therapy, hypoglycemic events were more frequently observed in cagrilintide arms than placebo arms. This is a critical safety consideration in any research protocol involving metabolically compromised subjects.

Gallbladder-Related Events

Cholelithiasis (gallstones) and related biliary events are a known class effect of significant weight loss achieved through any mechanism. Cagrilintide trials documented gallbladder-related events in a small but consistent subset of participants, particularly those experiencing rapid weight loss exceeding 1–1.5% of body weight per week. The frequency was comparable to what is observed with GLP-1 receptor agonists at similar weight loss magnitudes.

Rare but Serious Adverse Events

The following events occurred at low frequencies (typically under 1%) in clinical trials but carry significant clinical weight. Any research protocol involving cagrilintide should include monitoring parameters for these outcomes.

Severe Gastrointestinal Events

A small percentage of participants experienced severe nausea or vomiting requiring medical intervention, including IV fluid administration. In rare cases, participants discontinued the trial due to GI intolerability. Severe GI events were more common at the 4.5 mg dose, less common at the 2.4 mg maintenance dose used in phase 3 trials.

Acute Pancreatitis

Pancreatitis has been flagged as a theoretical concern with amylin-based compounds, as amylin is co-secreted with insulin by pancreatic beta cells. While clinical trial data on cagrilintide did not show a statistically significant increase in pancreatitis versus placebo, researchers flagged several cases for investigation. Given that pancreatitis is a known risk signal for the broader class of metabolic peptides, it remains a monitored outcome in ongoing phase 3 trials.

Severe Injection Site Reactions

While most injection site reactions were mild, rare cases of more significant local tissue responses were documented. These included larger indurated nodules, prolonged erythema, and in isolated cases, signs consistent with localized inflammatory reactions requiring medical evaluation. Proper injection technique and site rotation significantly reduces this risk.

Psychiatric and Mood Changes

Given cagrilintide's central nervous system activity, ongoing phase 3 monitoring includes psychiatric assessments. No significant rates of suicidality or severe mood disturbance emerged in published phase 2 data, but this remains an active monitoring parameter — consistent with FDA requirements for all weight management therapeutics.

How to Minimize Side Effects: Protocol Considerations

Clinical trial data consistently shows that dose escalation strategy is the single most important factor in cagrilintide tolerability. Protocols that escalated dose too quickly saw substantially higher rates of GI adverse events and discontinuation. The phase 3 trials used a gradual escalation schedule spanning 16 weeks before reaching the 2.4 mg maintenance dose, which produced the most favorable tolerability profile.

Frequently Asked Questions